The European Medicines Agency said the EU Clinical Trials Information System will require major redevelopment to align with the proposed EU Biotech Act. The EMA said the planned changes would affect roughly 70% of current CTIS functionality, with the goal of enabling faster assessments and greater flexibility for modifying ongoing studies.